|
Quotes & Info
|
| VNDA > SEC Filings for VNDA > Form 8-K on 26-Dec-2012 | All Recent SEC Filings |
26-Dec-2012
Change in Directors or Principal Officers
On December 19, 2012, the Compensation Committee of the Board of Directors (the "Compensation Committee") of Vanda Pharmaceuticals Inc. (the "Company") awarded 2012 annual bonuses to and approved 2013 annual base salaries and 2013 bonus target amounts for the Company's named executive officers. Prior to approving the foregoing, the Compensation Committee reviewed an analysis of the Company's executive compensation compared to the Company's peer group conducted by Towers Watson, a compensation consultant engaged by the Compensation Committee.
The Compensation Committee awarded bonuses for performance for the twelve-month period ending December 31, 2012, in the amounts set forth opposite the names of the executive officers listed below.
Name Position 2012 Bonus
Mihael Polymeropoulos, M.D. President and Chief Executive Officer $ 300,000
James Kelly Senior Vice President, Chief Financial
Officer $ 144,000
Robert Repella Senior Vice President and Chief
Commercial Officer $ 168,000
|
The Compensation Committee approved 2013 annual base salaries and 2013 bonus target amounts for the twelve-month period ending December 31, 2013, in the amounts set forth opposite the names of the executive officers listed below.
Name Position 2013 Base Salary 2013 Target Bonus
Mihael Polymeropoulos, M.D. President and Chief
Executive Officer $ 515,000 50% of 2013 Base Salary
James Kelly Senior Vice
President, Chief
Financial Officer $ 315,000 40% of 2013 Base Salary
Robert Repella Senior Vice
President and Chief
Commercial Officer $ 368,000 40% of 2013 Base Salary
|
|
|